Christopherm Chipman News Today

BERWYN, Pa.--(BUSINESS WIRE)--#earnings--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its...

--VRPX Intranasal Cannabidiol Product Candidate for Management of Epilepsy in Children and Adults--BERWYN, Pa.--(BUSINESS WIRE)--#pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress di...

--Company Highlights Development Timelines for Product Candidates--BERWYN, Pa.--(BUSINESS WIRE)--#earnings--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX) a company specializing in developing non-addictive product candidates for pain management, post-traumatic stress disorder, central nervou...

Virpax Pharmaceuticals Expands AnQlar™ Development and Commercialization Rights Through Worldwide Licensing Agreement - AnQlar ™ Has Previously Demonstrated... | March 20, 2022

- AnQlar Has Previously Demonstrated Antiviral Activity Against Influenza and SARS-CoV-2 in Three Preclinical Studies - -- The FDA has indicated that Virpax may pursue an NDA drug approval with

Virpax Pharmaceuticals: Virpax to Initiate Investigational New Drug (IND) Enabling Studies for Epoladerm BERWYN, PA / ACCESSWIRE / March 10, 2021 / Virpax ® Pharmaceuticals Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), today announced that it has signed an agreement with Charles River Laboratories to initiate preclinical studies of Epoladerm, Virpaxs proprietary, patented, anti-inflammatory topical spray film delivery technology for acute musculoskeletal pain. Under the terms of this agreeme...

WEST CHESTER, PA / ACCESSWIRE / March 2, 2021 / Virpax® Pharmaceuticals Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing pharmaceutical products for pain management

DGAP-News: Virpax(R) Pharmaceuticals Inc.: Virpax Begins IND Enabling Studies of Envelta(TM) vom 23.02.2021, 14:00 Uhr Bild: pixabay.com Virpax(R) Pharmaceuticals Inc.: Virpax Begins IND Enabling Studies of Envelta(TM) 23.02.2021 / 14:00 Virpax Begins IND Enabling Studies of Envelta(TM) WEST CHESTER, PA / ACCESSWIRE / February 23, 2021 / Virpax (R) Pharmaceuticals Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), today announced that according to the Cooperative Research and Development Agree...

Virpax Pharmaceuticals: Virpax Begins IND Enabling Studies of Envelta WEST CHESTER, PA / ACCESSWIRE / February 23, 2021 / Virpax ® Pharmaceuticals Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), today announced that according to the Cooperative Research and Development Agreement ("CRADA") entered into between Virpax and the National Center for Advancing Translational Sciences ("NCATS"), an institute/center of the National Institutes of Health ("NIH"), U.S. Department of Health and Human Servic...

Press release content from Accesswire. The AP news staff was not involved in its creation.